Biotech ETF Rises 17% in a Month Without NVIDIA
A biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
Determine which funds deliver the best annual risk-adjusted returns and how they stack up. Compare contenders to pick winners.
28,456 articlesA biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
Could a $10,000 stake in Nuscale Power really turn into a fortune? This deep dive weighs the math, the regulatory hur...
In May, nano nuclear energy powered stocks surged as collaborations with data centers and regulatory progress lifted ...
A sudden drop in Intuit's stock price can feel unsettling, but it may also open a window for patient investors. This ...
A dramatic seed-phrase leak led to a flurry of activity around seized wallets. This piece explores what happened, why...
Housing costs and fuel prices are digitizing the inflation picture. This article explains how shelter gasoline pushed...
With U.S. stocks marching higher, a quartet of ETFS paying yields while diversifies income and exposure beyond the S&...
BonkDAO reports a $20 million loss following a governance attack that exploited a proposal flaw. Upbit has paused BON...
Imagine Micron topping a trillion-dollar market cap. The market would react in unpredictable ways. This guide explain...
High‑net‑worth investors are leaning on tax‑aware planning this year. The playbook centers on advisor guidance, tax‑e...
Space-based power could unlock sustainable habitats beyond Earth. This guide explains what space nuclear power invest...
Pfizer signals it can bankroll ambitious deals with a robust balance sheet. This article weighs what a 'very big' bal...